+ All Categories
Home > Documents > Supplemental Figure 2 - Cancer Discovery · SUPPLEMENTAL FIGURE 2. Title: Supplemental Figure 2...

Supplemental Figure 2 - Cancer Discovery · SUPPLEMENTAL FIGURE 2. Title: Supplemental Figure 2...

Date post: 10-Jul-2020
Category:

Documents
Upload: others
View: 3 times
Download: 0 times
Download Report this document
Share this document with a friend
1
A 0 10 2 10 3 10 4 10 5 0 10 2 10 3 10 4 10 5 0 10 2 10 3 10 4 10 5 31% HLA-DR CD11b 41% 0 10 2 10 3 10 4 10 5 Ly6G + (E2) Ly6G + (Vh) B C Ly6C Ly6G 56.3% 4.0% 0.4% 1.1% Vh MPP SUPPLEMENTAL FIGURE 2
Transcript
Page 1: Supplemental Figure 2 - Cancer Discovery · SUPPLEMENTAL FIGURE 2. Title: Supplemental Figure 2 Created Date: 7/29/2016 10:43:37 AM ...

A

0 102 103 104 105

0

102

103

104

105

<Pacific Blue-A>: CD11b

0 102 103 104 105

0

102

103

104

105

<Pacific Blue-A>: CD11b

31%

HLA-DR

CD

11b

41%

0 102103

104105

<CellTraceViolet-A>: Cell Trace

Ly6G+ (E2)

Ly6G+ (Vh)

B

C

Ly6C

Ly6G

56.3%

4.0% 0.4%

1.1%

Vh MPPSUPPLEMENTAL FIGURE 2

Recommended
Supplemental Figure 1 A B panobinostat. OCI-AML3 Supplemental Figure 2 Control2050 nM BC2059, 24 hr A B.

Supplemental Figure 1 A B panobinostat. OCI-AML3 Supplemental Figure 2 Control2050 nM BC2059, 24 hr A B.

Documents

Supplemental Figure 1

Supplemental Figure 1

Documents

Supplemental Figure 2

Supplemental Figure 2

Documents

Figure Legends for Supplemental Figures Supplemental

Figure Legends for Supplemental Figures Supplemental

Documents

SUPPLEMENTAL FIGURE LEGEND - Weeblydimitrovagen677s09.weebly.com/uploads/1/7/2/1/...1 SUPPLEMENTAL FIGURE LEGEND Supplemental Figure 1. Absence of cardiac developmental abnormalities

SUPPLEMENTAL FIGURE LEGEND - Weeblydimitrovagen677s09.weebly.com/uploads/1/7/2/1/...1 SUPPLEMENTAL FIGURE LEGEND Supplemental Figure 1. Absence of cardiac developmental abnormalities

Documents

Supplemental Figure 1, related to Figure 1genesdev.cshlp.org/.../Supplemental_Figures.pdf · Supplemental Figure 2, related to Figure 2 (A-B) Full sequences of mouse Dll4in3 enhancer

Supplemental Figure 1, related to Figure 1genesdev.cshlp.org/.../Supplemental_Figures.pdf · Supplemental Figure 2, related to Figure 2 (A-B) Full sequences of mouse Dll4in3 enhancer

Documents

Supplemental materials 2 Supplemental Figure 1.Antibody ...dm5migu4zj3pb.cloudfront.net/manuscripts/66000/66824/JCI66824sd.pdf · Supplemental Figure . PRL5 -3 is expressed at higher

Supplemental materials 2 Supplemental Figure 1.Antibody ...dm5migu4zj3pb.cloudfront.net/manuscripts/66000/66824/JCI66824sd.pdf · Supplemental Figure . PRL5 -3 is expressed at higher

Documents

Supplemental Figure legends (revision-2) · Supplemental Figure legends Supplemental Fig. 1 Gating strategy for isolation of regulatory T cells. (A) A gate surrounding CD3-positive

Supplemental Figure legends (revision-2) · Supplemental Figure legends Supplemental Fig. 1 Gating strategy for isolation of regulatory T cells. (A) A gate surrounding CD3-positive

Documents

Supplemental Figure Legends: Supplemental Figure 1 ...dm5migu4zj3pb.cloudfront.net/manuscripts/59000/59743/JCI...31 Supplemental Figure Legends: Supplemental Figure 1. Caerulein treatment

Supplemental Figure Legends: Supplemental Figure 1 ...dm5migu4zj3pb.cloudfront.net/manuscripts/59000/59743/JCI...31 Supplemental Figure Legends: Supplemental Figure 1. Caerulein treatment

Documents

Supplemental Figure 1 A. · Supplemental Figure 1 A. B. Let-7 target site C. miR-103/107 target site . 2 Supplemental Figure 2 . 3 Supplemental Figure 3 . 4 Supplemental Figure 4

Supplemental Figure 1 A. · Supplemental Figure 1 A. B. Let-7 target site C. miR-103/107 target site . 2 Supplemental Figure 2 . 3 Supplemental Figure 3 . 4 Supplemental Figure 4

Documents

Supplemental Figure 1 - Journal of CancerSupplemental Figure 2 . Supplemental Figure 3 . Supplemental Table 1. Relationship between CD4 TIL expression and various patient characteristics

Supplemental Figure 1 - Journal of CancerSupplemental Figure 2 . Supplemental Figure 3 . Supplemental Table 1. Relationship between CD4 TIL expression and various patient characteristics

Documents

Supplemental Figures Supplemental Figure 1€¦ · Supplemental Figures . Supplemental Figure 1 . Supplemental Figure 1. AdipoChaser mouse models used for cold and thermoneutral exposures.

Supplemental Figures Supplemental Figure 1€¦ · Supplemental Figures . Supplemental Figure 1 . Supplemental Figure 1. AdipoChaser mouse models used for cold and thermoneutral exposures.

Documents

Supplemental Information Recruitment of UBPY and ESCRT ...Supplemental Movie 2, related to Figure 1(available online) Supplemental Movie 3, related to Figure 1(available online) Supplemental

Supplemental Information Recruitment of UBPY and ESCRT ...Supplemental Movie 2, related to Figure 1(available online) Supplemental Movie 3, related to Figure 1(available online) Supplemental

Documents

Figure I supplemental

Figure I supplemental

Documents

Supplemental Information - CLST labs websites material_JBO2015.pdfSupplemental figure Figure S1 – S3 2 / 10 Supplemental experimental procedures Conditions for automated tracking

Supplemental Information - CLST labs websites material_JBO2015.pdfSupplemental figure Figure S1 – S3 2 / 10 Supplemental experimental procedures Conditions for automated tracking

Documents

Supplemental Figure 5

Supplemental Figure 5

Documents

Supplemental Figure S1

Supplemental Figure S1

Documents

Supplemental Information Table of Contents Supplemental ...genesdev.cshlp.org/.../Supplemental_Data.pdf · Qiao_Supplemental Figure 2, related to Figure 2. (A) Loss of REDD1 confers

Supplemental Information Table of Contents Supplemental ...genesdev.cshlp.org/.../Supplemental_Data.pdf · Qiao_Supplemental Figure 2, related to Figure 2. (A) Loss of REDD1 confers

Documents